ASCO 2014: Dr. Hope S. Rugo gives her top picks in breast cancer research

1. Abstract LBA1, Olivia Pagani et al.

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs. tamoxifen (T) plus OFS in premenopausal women with hormone receptor–positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. http://abstracts.asco.org/144/AbstView_144_129398.html

2. Abstract LBA4, Martine J. Piccart-Gebhart et al.

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T?L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).

http://abstracts.asco.org/144/AbstView_144_128258.html

3. Abstract LBA505, Halle C.F. Moore et al.

Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor–negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance).

http://abstracts.asco.org/144/AbstView_144_129172.html

4. Abstract 503, Hongchao Pan et al.

Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials.

http://abstracts.asco.org/144/AbstView_144_133648.html

Covered at premeeting press briefing, Oncology Practice report here.

5. Abstract 1005, Gunter Von Minckwitz et al.

Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.

http://abstracts.asco.org/144/AbstView_144_131770.html

6. Abstract 516, Ingrid A. Mayer et al.

SU2C phase Ib study of the PI3K-alpha inhibitor BYL719 with letrozole in ER+/HER2– metastatic breast cancer (MBC).

http://abstracts.asco.org/144/AbstView_144_130044.html

7. Abstract 1016, G. Thomas Budd et al.

Outcome of male patients and black patients enrolled in S0221, an intergroup chemotherapy study.

http://abstracts.asco.org/144/AbstView_144_128157.html

Dr. Hope S. Rugo is a professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.

1. Abstract LBA1, Olivia Pagani et al.

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs. tamoxifen (T) plus OFS in premenopausal women with hormone receptor–positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. http://abstracts.asco.org/144/AbstView_144_129398.html

2. Abstract LBA4, Martine J. Piccart-Gebhart et al.

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T?L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).

http://abstracts.asco.org/144/AbstView_144_128258.html

3. Abstract LBA505, Halle C.F. Moore et al.

Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor–negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance).

http://abstracts.asco.org/144/AbstView_144_129172.html

4. Abstract 503, Hongchao Pan et al.

Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials.

http://abstracts.asco.org/144/AbstView_144_133648.html

Covered at premeeting press briefing, Oncology Practice report here.

5. Abstract 1005, Gunter Von Minckwitz et al.

Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.

http://abstracts.asco.org/144/AbstView_144_131770.html

6. Abstract 516, Ingrid A. Mayer et al.

SU2C phase Ib study of the PI3K-alpha inhibitor BYL719 with letrozole in ER+/HER2– metastatic breast cancer (MBC).

http://abstracts.asco.org/144/AbstView_144_130044.html

7. Abstract 1016, G. Thomas Budd et al.

Outcome of male patients and black patients enrolled in S0221, an intergroup chemotherapy study.

http://abstracts.asco.org/144/AbstView_144_128157.html

Dr. Hope S. Rugo is a professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.

1. Abstract LBA1, Olivia Pagani et al.

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs. tamoxifen (T) plus OFS in premenopausal women with hormone receptor–positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. http://abstracts.asco.org/144/AbstView_144_129398.html

2. Abstract LBA4, Martine J. Piccart-Gebhart et al.

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T?L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).

http://abstracts.asco.org/144/AbstView_144_128258.html

3. Abstract LBA505, Halle C.F. Moore et al.

Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor–negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance).

http://abstracts.asco.org/144/AbstView_144_129172.html

4. Abstract 503, Hongchao Pan et al.

Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials.

http://abstracts.asco.org/144/AbstView_144_133648.html

Covered at premeeting press briefing, Oncology Practice report here.

5. Abstract 1005, Gunter Von Minckwitz et al.

Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.

http://abstracts.asco.org/144/AbstView_144_131770.html

6. Abstract 516, Ingrid A. Mayer et al.

SU2C phase Ib study of the PI3K-alpha inhibitor BYL719 with letrozole in ER+/HER2– metastatic breast cancer (MBC).

http://abstracts.asco.org/144/AbstView_144_130044.html

7. Abstract 1016, G. Thomas Budd et al.

Outcome of male patients and black patients enrolled in S0221, an intergroup chemotherapy study.

http://abstracts.asco.org/144/AbstView_144_128157.html

Dr. Hope S. Rugo is a professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.